Business
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
September 9-11, 2024 STATEN ISLAND, N.Y., Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), today announced it will be featured as a
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"September 9-11, 2024\nSTATEN ISLAND, N.Y., Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), today announced it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024. \n\nThe in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.\nDavid P. Luci, President & CEO of the Company, will provide an overview of the Company's business during the presentation.\nIf you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference. Over 550 corporate presentations & panels are available during September 9-11, 2024.\nEvent: H.C. Wainwright 26th Annual Global Investment Conference\nDate: September 9-11, 2024\nLocation: Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person location date/time at the Lotte New York Palace Hotel, New York, NY.\nAbout Acurx Pharmaceuticals, Inc. \nAcurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).\nTo learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.\nAbout H.C. Wainwright & Co. \nH.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trad...